Serina’s development updates on a polymer drug-delivery platform and a Parkinson’s therapy candidate, plus the company’s upcoming investor outreach.
Key Takeaways
- Serina Therapeutics will participate in the BTIG Virtual Biotechnology Conference on 28-29 July 2026
- POZ-apomorphine candidate intended to provide continuous dopaminergic stimulation for Parkinson’s disease
- Serina is a clinical-stage biotechnology company listed on NYSE American under SER and is headquartered in Huntsville